HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease, according to findings ...
A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Zacks Investment Research on MSN1d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback